$JNJ

Dividend Kings Johnson & Johnson and AbbVie offer 50+ years of consecutive dividend growth with resilient pipelines successfully offsetting patent expirations.

Vanguard's $VYM offers lower fees and broader diversification with stronger recent returns, while iShares' $HDV delivers higher dividend yield through concentrated energy and defensive holdings.

Johnson & Johnson submits EMA application for TECVAYLI monotherapy in relapsed/refractory multiple myeloma, citing 71% risk reduction in disease progression or death versus standard care.

Global orthobiologics market projected to grow 43% to $9.52B by 2031, driven by rising osteoarthritis and regenerative therapy advancements.

$JEPI ETF generates 8%+ yields using covered call strategies, dramatically outpacing traditional dividend yields of 1-2%, though investors sacrifice capital appreciation upside.

Three dividend aristocrats—$GPC, $KMB, and $TGT—offer attractive yields and growth catalysts for income-focused investors in March 2026.

Johnson & Johnson and Zoetis identified as premier dividend stocks for income investors, citing consistent growth, innovation pipelines, and demographic tailwinds.

Seven Wall Street leaders collectively distribute $114 billion yearly to shareholders. Microsoft tops the list with $27.1 billion in dividends despite modest yield.

U.S. jobs fell 92,000 in February amid unemployment rise, geopolitical tensions, and AI concerns, triggering institutional rotation into defensive healthcare, utilities, staples, energy, and defense stocks.

FDA approves J&J's Tecvayli plus Darzalex Faspro for multiple myeloma with 83.3% three-year survival rate, expanding drug's label.

Global cytokines market projected to grow from $95.32B (2025) to $174.53B (2032) at 9.02% CAGR, driven by manufacturing advances and strategic partnerships.

Escalating Middle East tensions drive investors to defensive stocks including defense contractors, energy majors, consumer staples, and utilities offering stability and income.

AbbVie's Skyrizi achieved 55% remission rate in Crohn's patients versus 30% placebo, strengthening competitive positioning against Johnson & Johnson's Tremfya.

Global antibiotics market to grow from USD 55.60B in 2025 to USD 70.64B by 2031 at 4.07% CAGR, driven by antimicrobial resistance and innovation.

Colorectal cancer deaths surge among Americans under 50, becoming the leading cancer killer in this age group. An awareness campaign installs 27,000 blue flags on the National Mall.

BMS's Sotyktu shows promise for psoriatic arthritis among one-third of surveyed rheumatologists, but analysts expect modest market capture ahead of March 2026 FDA decision.

Medical device cleaning market projected to nearly double to $3.74B by 2032, driven by stricter infection control regulations and shift toward reusable devices in healthcare.

Advanced drug delivery systems market projected to grow from $299.6B (2025) to $487.4B (2030), driven by chronic diseases, nanotechnology breakthroughs, and oncology applications.

J&J stock hits record highs with 14% monthly returns, outperforming tech due to stable dividends, strong cash flow, and lower volatility amid market uncertainty.

Alpine Capital Research increased its Arrow Electronics stake to 5.9% of AUM ($379M) in Q4 2025, reflecting confidence in the tech distributor's strong operational momentum and financial performance.